Uscom

Proactive Investors

September 2015

Uscom (UCM) – Medical Devices and Revenue Growth

Rob Phillips

PhD(med), MPhil(med), FASE, DMU(cardiol)

Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland

Executive Chairman/CEO

The Measure of Life

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

While Uscom (the "Company”) has taken due care in compiling the information, neither the Company nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Company. Certain information may relate to protected intellectual property rights owned by Uscom. By viewing this presentation the viewer accepts the terms of the accompanying Company NDA. The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.

Uscom

Products generate profit

High growth (+50%), innovative medical device company
Poised for strategic growth with recent acquisitions
Valuable IP with high margins (75+%)
Targeting key cardiovascular markets with multiple products
Undervalued - $15m market cap
US growth from new products
Fundamentals to drive value

USCOM helps to save baby's life in Nottingham
https://youtu.be/bJXx5nmUeF8

Uscom Vision

Company of the Year, 2014
Johnson & Johnson Innovation Industry Excellence Awards

"A milestone driven global medical device company with real products, real revenue, real growth and an aggressive growth strategy"

Johnson & Johnson INNOVATION

AusBiotech
AUSTRALIA'S BIOTECHNOLOGY ORGANISATION

Current Business

- Premium noninvasive cardiovascular and pulmonary monitoring devices
- Addressing the growing threat of superbugs, heart failure, hypertension and asthma
- Validated, clinically accepted, cost and life saving devices
- Patent protected with regulatory approvals
- Uscom BP+ for market 2016 - $7m over 5years Chinese contract in place
- Rapidly growing revenues in major markets and new untouched markets

Corporate

- ASX listed (UCM)
- Headquartered in Sydney
- Market cap of $15m
- 92m shares on issue
- Rob Phillips, Founder and CEO, holds 20% of company

Board & Management

- Rob Phillips, Chairman & CEO
- Sheena Jack, Director (HCF, Moneytime Health)
- Christian Bernecker, Director (Stream)
- Nick Schicht, General Manager

Financials

- Sales +58% 2015
- Revenue +48% 2015 ($2+m)
- Cash consumption - $1m
- Gross Margins ~ 78%
- Cash $2.5m

* Uscom Annual report

Uscom

Operational growth





Distribution – sales – revenue

Thor adds distribution and revenue

* FY to date

Uscom

Maintaining growth

Operations growth

1. Uscom Limited
2. Uscom UK
3. Uscom Budapest
4. Uscom Inc US



Key Markets

1. AsiaPAC – 65%
2/3. Europe – 27%
4. Nth America – 8%

US Focus 2016

Stephen Wilson – Former VP Corporate Development Welch Allyn appointed



Uscom

Strategic growth

Complementary products and technology

Fluid, Sepsis & Heart Failure

- US 1.3bn market *
- CAGR of 7.6% *
- CE, FDA, TGA, CFDA

Hypertension & Vascular Health

- US 1.7bn market *
- CAGR of 11.5% *
- CE, FDA, TGA

COPD & Asthma

- US 400m market *
- CAGR of 6.5% *
- CE, TGA, FDA

USCOM 1A

Cardiac Output Monitoring

BP+

Blood Pressure Monitoring

Acquired July 2013

Aus competitor - $50m

Thor

Pulmonary Monitoring

Acquired August 2015

* Source: MedTech Insight; Transparency Market Research

Uscom

New Acquisition

THOR laboratories

Uscom has acquired 100% of Thor Laboratories - Asthma[*]

Company Overview

- High fidelity digital Doppler spirometry devices
- Established manufacturing - 15 years
- Global reach
- Reimbursement in multiple markets
- Strong R&D and grant history
- Partners in Home Care Asthma in the USA

Uscom benefits

- Cash flow positive, revenue of $500k
- Accredited international manufacturing
- 4 + 3 products, CE, FDA, TGA approvals
- Global distribution
- Technical R&D team 12 engineers
- Marketing and management

Synergy of science, operations and strategy

* Agreement subject to DD and Uscom capital raise

New Products - Asthma

Aus competitor $75m

Products in Market

Digital Doppler Spirometer
Home use

With Diagnostics and WIFI
Digital wifi spirometer

Professional System
Desktop with advanced software analytics



New Products

New – AsthmaHero
Drug delivery measure
Telemetry to iPhone app
Smart spacer
Patient interactive

cohero health
breathe smarter

New - BreatheSmart
Digital wifi spirometer
Remote clinical monitoring
Cloud diagnosis

New - Whistler
Neonatal Asthma diagnostic

Uscom

Revenue Growth Targets



Thor

BP+

USCOM

$20m revenue by 2020 - 5 year CAGR of 58%

Uscom

The Future

Value Cascade

Products	Sales	Operations	Options
USCOM 1A Uscom BP+ Spirotube Otthon SpiroDesk BreatheSmart AsthmaHero ThorSoft	Current distribution Thor distribution New distribution Major partners	Global operations Revenue growth Profitability	Dividend Share price growth Transaction

Products – Sales – Revenue - Opportunities

Uscom

Business Risks & Mitigants

Risks

- Global markets unpredictable
- Thor integration & key staff retention
- Ongoing Thor business management
- Competitiveness of market sectors
- Thor distraction from USCOM & BP+
- Regulatory costs and timelines
- Distribution & revenue growth
- Working capital requirements to meet increased product demand

Mitigants

- Diversified and expanded products
- Earn outs in Thor deal structure
- Earn outs in Thor deal structure
- Senior sales and marketing personell
- Product diversification
- Resources focussed on integration
- Key Uscom and Thor staff
- Senior sales and marketing resource
- Additional WC in capital raise

Uscom

UCM Investment



UCM sales growth

*2014 – **67%***

*2015 – **59%***

Health outperforms!

* Dividend exclusive

Market anomaly - opportunity

Opposing forces!

Disconnect between performance and price





Unrecognised value

* Estimate

Uscom

Uscom

Under valued ✓

Strong growth phase ✓

Positioned for on going growth ✓

Strong underlying business ✓

Premium global markets ✓

Lifesaving technologies ✓

Sector leading management ✓

Aggressive global growth strategy ✓

Right time/value investment ✓

Uscom

Uscom

Proactive Investors

September 2015

Uscom (UCM) – Medical Devices and Revenue Growth

Thanks

Rob Phillips

PhD(med), MPhil(med), FASE, DMU(cardiol)

Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland

Executive Chairman/CEO